<?xml version="1.0" encoding="UTF-8"?>
<p>Although there has been almost no evidence on the use of statins in patients with SARS-CoV-2, these drugs have previously been investigated in the treatment of other acute respiratory viral infections such as influenza [
 <xref rid="B37-jcm-09-01909" ref-type="bibr">37</xref>,
 <xref rid="B38-jcm-09-01909" ref-type="bibr">38</xref>,
 <xref rid="B39-jcm-09-01909" ref-type="bibr">39</xref>]. A study of 1055 adult patients with viral pneumonia found lower rates of mortality and intubation with continued use of statins throughout the hospital stay (odds ratio (OR) 0.26; 95% confidence interval (CI): 0.08–0.81) [
 <xref rid="B37-jcm-09-01909" ref-type="bibr">37</xref>]. Similar to SARS-CoV, hepatitis C viral (HCV) replication is closely associated with lipid metabolism, and statins are expected to disrupt this mechanism [
 <xref rid="B40-jcm-09-01909" ref-type="bibr">40</xref>]. Statin treatment in chronic HCV was shown to increase the clearance of the virus from the blood, down-regulate HCV replication [
 <xref rid="B41-jcm-09-01909" ref-type="bibr">41</xref>], and resulted in clinical reduction in hepatocellular carcinoma [
 <xref rid="B41-jcm-09-01909" ref-type="bibr">41</xref>,
 <xref rid="B42-jcm-09-01909" ref-type="bibr">42</xref>]. Additionally, a meta-analysis by Chopra et al. showed that statin use was associated with lower mortality after pneumonia (OR 0.62, 95% CI: 0.54–0.71) [
 <xref rid="B43-jcm-09-01909" ref-type="bibr">43</xref>]. 
</p>
